Clinical Decision-Making when Treating Diabetic Macular Edema Patients with Dexamethasone Intravitreal Implants
| Autor: | Alfredo García-Layana, Félix Armadá, Rafael Navarro, Marta S. Figueroa, Álvaro Fernández-Vega, Juan Peralta Donate, Rufino Silva, José M. Ruiz-Moreno, E. Cervera, Luis Arias, Maximino Abraldes, Alfredo Adán, Francisco Cabrera |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Visual acuity genetic structures Clinical Decision-Making Visual Acuity Dexamethasone Macular Edema 03 medical and health sciences 0302 clinical medicine Internal medicine Diabetes mellitus Dexamethasone Intravitreal Implant Medicine Humans Macular edema Glucocorticoids Drug Implants Diabetic Retinopathy business.industry General Medicine Diabetic retinopathy medicine.disease eye diseases Sensory Systems Pathophysiology Ophthalmology 030104 developmental biology Intravitreal Injections 030221 ophthalmology & optometry medicine.symptom business Tomography Optical Coherence medicine.drug Medical literature |
| Zdroj: | Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde. 240(2) |
| ISSN: | 1423-0267 |
| Popis: | Diabetes mellitus (DM) is a metabolic disease frequently associated with comorbidities that include diabetic macular edema (DME). The current medical approach to treating DME involves intravitreal injections with either anti-vascular endothelial growth factors or steroids. However, the burden associated with intravitreal injections and DM-derived complications is high, underlining the need to find optimal treatment regimens. In this article we describe the considerations we apply when treating DME patients with dexamethasone intravitreal implants (Ozurdex®), particularly those that influence the clinical decision-making process during the follow-up period. These considerations are based both on the available medical literature and on our clinical experience following the use of these implants in this type of patient, the goal being to optimize the number of injections and the clinical outcome of this therapy. We also provide a general overview of the pathophysiology of DME, highlighting the inflammatory component as a rationale to use steroids in these patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|